Cadila Healthcare clarifies on news item

13 Nov 2017 Evaluate

The Exchange had sought clarification from Cadila Healthcare with respect to news appearing in www.livemint.com on November 10, 2017 titled ‘Zydus Cadila, Intas under scanner for launching hypertension drug without permit’. The company response is enclosed.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

885.05 -13.70 (-1.52%)
19-Mar-2026 09:23 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1770.50
Dr. Reddys Lab 1274.20
Cipla 1248.80
Zydus Lifesciences 885.05
Lupin 2284.95
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×